Both ERAP1 and ERAP2 have been shown to be downregulated in some cancers [265], play key roles in the shaping of the cellular immunopeptidome [85], and their activity has been associated with changes in anti-cancer immune responses [101]. Here, ERAP2 is linked to cancer.